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Abstract
Dendritic cells (DC) play an integral role in plasmid DNA vaccination. However, the interaction between plasmid DNA and DC in vivo is
incompletely understood. In this report, we utilise the sheep pseudoafferent cannulation model to examine the interaction between plasmid
DNA encoding enhanced green fluorescent protein (pEGFP) and afferent lymph DC (ALDC) following gene gun administration. The results
show that peaks of fluorescent ALDC tended to appear around days 1–4 and 9–13, then erratically thereafter for up to 2 months. Phenotypic
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dnalysis showed that EGFP+ ALDC expressed MHC class II, WC6, CD1b, and SIRP markers. Plasmid, detected by PCR, was found in
ymph cells and cell-free plasma on a daily basis, and was present variably for up to 2 months. Plasmid was also detected in purified CD1b+
LDC, but the presence of plasmid did not correlate with EGFP expression by ALDC. Free EGFP in afferent lymph plasma was detectable
y luminometry only after three administrations of the plasmid. The results show that gene gun administered pEGFP persisted for extended
eriods after a single administration, leeching out of skin on a daily basis. The plasmid was associated with both the cellular and fluid
omponents of afferent lymph. EGFP protein appeared in afferent lymph in a pulsatile manner, but associated only with ALDC.
2005 Elsevier Ltd. All rights reserved.
eywords: Enhanced green fluorescent protein; Sheep; Gene gun; Dendritic cells
. Introduction
Plasmid DNA vaccination is a novel strategy for induc-
ng protective immune responses against a wide variety of
athogens [1]. A major advantage of DNA vaccination is
hat both humoral and cytotoxic immune responses are gen-
rated. However, immune responses to DNA vaccines are
ften weak and/or short lived particularly in humans or live-
tock [2]. For these obstacles to be overcome, a greater un-
erstanding of the mechanisms involved is required. Several
tudies have demonstrated an obligate role for bone marrow-
erived cells in presenting the encoded antigen to T cells
3–5]. Other studies have demonstrated that induction of pri-
ary and memory responses were due to rapidly migrating
∗ Corresponding author. Tel.: +44 131 6508802; fax: +44 131 4455770.
E-mail address: Gordon.Harkiss@ed.ac.uk (G. Harkiss).
1 Present address: Moredun Research Institute, Pentland Science Park,
ush Loan, Penicuik, Midlothian EH26 0PZ, UK.
cells from skin following gene gun administration or injection
of plasmid [6,7]. In the case of particle bombardment, this was
the case irrespective of whether the antigen was membrane-
bound, secreted, or intracellular [6]. Raz et al. [8] showed
that after intradermal injection of plasmid, cells resembling
macrophages or dendritic cells (DC) as well as keratinocytes
and fibroblasts were transfected. Other studies showed that
direct transfection of skin DC occurred following gene gun
administration [9,10]. In contrast, Corr et al. [11] provided
evidence that in vivo priming of immune responses follow-
ing injection of plasmid occurred predominantly by antigen
transfer. Thus, after DNA vaccination, DC appear to acquire
antigen either by direct transfection or by cross priming.
Condon et al. [9] showed that gene gun immunization
results in the localisation of transfected skin-derived DC
in the draining lymph nodes. Recently, it has been shown
that relatively high numbers of skin DC transfected by gene
gun lodge in the draining lymph nodes [12]. However, the
role of afferent lymph DC (ALDC) in DNA vaccination
264-410X/$ – see front matter © 2005 Elsevier Ltd. All rights reserved.
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has not been examined. ALDC can be accessed in sheep
via the technique of pseudoafferent lymphatic cannulation
[13,14]. Afferent lymph normally contains 3–10% ALDC,
<1–3% neutrophils and 87–96% lymphocytes [15]. The
ALDC are characterised by their high forward and side
scatter properties, expression of MHC class II and DEC205
(designated WC6 in ruminants) [13,16,17], and lack of ex-
pression of macrophage markers, such as CD14 and CD11b
[17,18]. Usually, around 60–70% of ALDC express CD1b
[13] and between 60 and 90% express SIRP [17,19]. In the
present study, we have used the pseudoafferent cannulation
model in sheep and a reporter plasmid encoding enhanced
green fluorescent protein (pEGFP) to examine reporter gene
expression following gene gun administration to skin. We
show that substantial numbers of ALDC exhibit EGFP flu-
orescence and that both EGFP-positive DC and free plasmid
continue to drain the vaccination site for up to 2 months.
2. Materials and methods
2.1. Pseudoafferent lymphatic cannulation
The prefemoral lymph node of 18-month-old Suffolk or
Finnish-landrace sheep (n= 11) was excised, and 6 weeks
later the pseudoafferent lymphatic duct cannulated as de-
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were optimised before use. One hundred micrograms pEGFP
(1 mg/ml stock in 1×TE pH 8.0) and 100l 0.05 M spermi-
dine were mixed with 20 mg 1.0 gold beads. One hundred
microlitres of 1 M CaCl2 was slowly added to precipitate the
pEGFP on to the beads, which were then washed five times in
100% ethanol (spinning at 1800× g, 15 s between washes).
The beads were resuspended in 2.4 ml ethanol containing
0.05 mg/ml PVP, and bound to the inner surface of plastic
tubing. Plasmid function of the pEGFP-coated gold beads
was assessed in ovine skin fibroblasts in vitro following gene
gun administration by flow cytometry and RT-PCR.
2.3. In vivo administration of pEGFP
The pEGFP-coated particles were targeted towards the
dermal–epidermal junction at a pressure of 500 psi using
a pressurised helium source. Each vaccination consisted of
five shots around the prefemoral afferent lymphatic drainage
area, resulting in a total of around 15g of pEGFP coated on
0.5 mg of gold beads being introduced into the skin. A tem-
plate was used to standardise the distance between adminis-
tration site and cannulation site and thus minimising variation
between sheep. To demonstrate that pEGFP coated onto gold
beads was functional in vivo, the plasmid was administered
via the gene gun to two sheep three times at weekly inter-
vals. The animals were primed with about 15g of pEGFP
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Pcribed previously [13]. Cannulations were allowed to sta-
ilise for at least 7 days prior to the start of the experiments.
fferent lymph was collected using heparinized cannula and
ottles. Total volumes of lymph collected were recorded on
daily basis. The total number of ALDC was determined by
ow cytometry.
.2. Plasmid
The plasmid pEGFP-C1 encoding a red shifted variant
f green fluorescent protein (EGFP) under the control of a
MV immediate early promoter was obtained from Clontech
Basingstoke, Hants, UK). The plasmid was transformed into
ompetent Escherichia coli DH5 cells and purified using a
egaprep kit from Qiagen Ltd. (Crawley, West Sussex, UK)
ccording to the manufacturer’s instructions. A control plas-
id DNA encoding -galactosidase (-gal), obtained from
lontech, was produced in a similar manner. Plasmid func-
ion was assessed in ovine skin fibroblasts in vitro by flow
ytometry and/or RT-PCR, following either electroporation
r gene gun administration. The -gal plasmid was assessed
y staining for -gal on cytosmears of the fibroblasts. The fi-
roblasts were cultured in DMEM supplemented with 2 mM
nal concentration of l-glutamine, 100 units/ml penicillin,
00g/ml streptomycin and 5% fetal calf serum at 37 ◦C,
% CO2.
A Helios (BioRad), helium powered, gene gun was used to
ropel pDNA-coated gold beads that were prepared accord-
ng to the manufacturer’s instructions. The gene gun param-
ters (pressure, particle size/number and PVP concentration)n the flank, and boosted with similar amounts 1 and 2 weeks
ater. Blood samples were taken before immunisation and 1
eek after the last boost. Anti-EGFP antibodies in titres up
o 1/4000 were detected in serum by Western blotting using
ecombinant EGFP (rEGFP) (Clontech) as antigen.
.4. Flow cytometry
Flow cytometry analyses were performed using a Bec-
on Dickson FACScan machine and the CELLQUEST soft-
are. Afferent lymph cells were harvested (350× g/5 min)
rom 10 ml of afferent lymph, washed three times in sterile
BS containing 2% bovine serum albumin and resuspended
n 5 ml sterile PBS/2% BSA. Live gates based on high side
catter and forward scatter were used in the flow cytometric
nalysis of ALDC [13]. EGFP fluorescence by ALDC was
etermined using the same excitation and emission wave-
engths as fluorescein isothiocyanate (FITC). Immunostain-
ng of ALDC was performed using monoclonal antibodies
o MHC class II DRB (SW73.2 [13]), CD11b (IAH-CC125
18]), WC6/DEC205 (IL-A53 [16]), CD1b (VPM5 [16]),
nd SIRP (IL-A24 [17]). Isotype-matched irrelevant mono-
lonal antibodies or normal mouse or rat serum diluted 1/1000
ere used as negative controls as appropriate. Cells from af-
erent lymph (10 ml) were prepared essentially as previously
escribed [13]. Briefly, cells were pelleted by centrifugation
350× g/5 min), washed twice in sterile phosphate-buffered
aline containing 1% bovine serum albumin (PBS-1% BSA)
nd resuspended at a concentration of 1.0× 107 cells/ml in
BS-1% BSA. Optimised dilutions of monoclonal antibodies
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were incubated with 5.0× 106 cells in 0.5 ml PBS-1% BSA
for 20 min at 4 ◦C. The cells were then washed three times in
1 ml PBS-1% BSA. The cells were incubated in a 1:250 di-
lution of anti-mouse-biotin (Sigma Chemical Company), for
20 min at 4 ◦C, washed and incubated in a 1:250 dilution of
phycoerythrin–streptavidin (Sigma Chemical Company) for
a further 20 min, washed and then analysed by flow cytometry
(approximately 10,000 cells counted per tube).
2.5. Puriﬁcation of CD1+ ALDC
CD1b+ ALDC were purified by magnetic activated cell
sorting (MACS). One hundred millilitres of afferent lymph
were centrifuged at 1750× g for 15 min at 4 ◦C. The cells
were resuspended in 5 ml of cold PBS/1% BSA, 5 mM EDTA,
0.1% sodium azide, and layered onto a 14.5% metrizamide
cushion in the same buffer. The interface cells were removed
and washed in 10 ml buffer then resuspended in buffer to
concentration of 1× 108 cells per ml. One millilitre was cen-
trifuged at 1500 rpm for 5 min, and the cells resuspended in
0.5 ml buffer. The cells were incubated with a 1:50 dilution
of VPM5-biotin for 30 mins at 4 ◦C. The cells were washed
three times, resuspended in 0.5 ml buffer, then incubated with
MACS streptavidin beads for 30 mins at 4 ◦C and loaded onto
a MACS RS+ column (Miltenyi Biotech). The bound cells
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from CD1b+ ALDC purified cells was similarly extracted.
Plasmid DNA was also extracted from 2 ml of cell free af-
ferent lymph. Afferent lymph was centrifuged at 10000× g,
for 5 min, at room temperature. The supernatant was passed
through a DNA miniprep column (Qiagen). Following the
manufacturer’s instructions, pDNA was eluted with 50l of
10 mM Tris pH 8.5 and used in the PCR reaction.
DNA containing pEGFP-C1 was amplified by PCR us-
ing forward and reverse primers. Forward primer: 5′-AAA-
AAC-CTC-CCA-CAC-CTC-C-3′; Reverse primer: 5′-TCC-
ACA-CCC-TAA-CTG-ACA-CAC-3′ The reaction mixture
contained 2l of 10× reaction buffer (New England Biolabs,
Hitchen, Herts, UK), 0.2l 100 mM dNTPs (final concentra-
tion of 5 pMol), 1 ng of the phenol extracted DNA, 2.0l Vent
polymerase at 2000 units/ml (2 units/20l reaction) and was
made up to 20l with water. The mix was heated to 95 ◦C
for 5 min to separate the double-stranded DNA and cooled
to 58 ◦C, before the Vent polymerase was added. The PCR
programme was as follows: 95 ◦C for 1 min, 58 ◦C for 1 min,
72 ◦C for 1.5 min, for 25 cycles. A final 5 min, 72 ◦C elonga-
tion phase completed the reaction (Hybaid Omnigene). The
reaction products were run on a 1.2% agarose gel, stained
with ethidium bromide and photographed under UV light. A
positive control used pEGFP instead of the extracted DNA,
whilst a negative control contained no DNA. The sensitivity
of the PCR was as follows: pEGFP diluted in water, 3.25 pg;
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cere washed and eluted in 1 ml buffer. The eluted cells were
pun at 350× g at 4 ◦C and resuspended in 0.2 ml buffer. Im-
unostaining performed with VPM5 showed that >95% of
he purified cells were CD1b positive.
.6. Luminometry
Cells were removed from afferent lymph by centrifuga-
ion at 350× g, for 5 min, at 4 ◦C and EGFP fluorescence in
he supernatant (2 ml) was measured by luminometry using
Perkin-Elmer Luminescence LS 50B Spectrophotometer.
he excitation and emission wavelengths were set at 488 nm
nd 509 nm, respectively. A standard curve of fluorescence
ersus rEGFP concentration (0–100 pg/ml) was established
sing afferent lymph plasma spiked with rEGFP.
.7. PCR
Cellular DNA was isolated from 5 ml of afferent lymph
lasma. The afferent lymph cells were pelleted by centrifu-
ation (350× g/5 min), washed three times in sterile PBS and
ysed in 200l of cell lysis buffer (1.28 M sucrose, 40 mM
ris–Cl, pH 7.5, 20 mM MgCl2, 4% Triton X-100) precooled
o 4 ◦C and 600l precooled dH2O added. The lysing cells
ere mixed by inversion and incubated on ice for 10 min be-
ore being pelleted by centrifugation at 1300× g, for 15 min,
t 4 ◦C, to remove nuclei. The supernatant was passed through
DNA miniprep column (Qiagen) following the manufac-
urer’s instructions and the plasmid eluted in 50l of 10 mM
ris pH 8.5 and used in the PCR reaction. Plasmid DNAEGFP spiked afferent lymph cell extract, 100 pg; pEGFP
piked cell free afferent lymph extracts, 10 pg.
.8. Statistical analyses
Statistical analyses were performed using the Mann-
hitney rank test.
. Results
.1. Phenotypic characterisation of ALDC
A live gate was placed around cells exhibiting high side
nd forward scatter by flow cytometry as described previously
13]. An example of the gate and the results of immunostain-
ng are shown in Fig. 1. The gated cells were almost all pos-
tive for MHC class DR and showed high intensity staining.
he gated afferent lymph cells were also almost all positive
or the pan DC marker WC6 and negative for the macrophage
arker CD11b. About 75% of ALDC were SIRP+ in this
xample. These staining patterns are consistent with previous
tudies of ALDC in sheep, cattle, mice and humans [15–21].
.2. EGFP ﬂuorescence by ALDC following pEGFP
dministration
To investigate whether ALDC expressed EGFP fluores-
ence following administration of pEGFP, eight sheep re-
eived approximately 10–15 mg of plasmid DNA distributed
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Fig. 1. ALDC characterization. ALDC were characterized using a live gate based on high forward and side scatter (boxed area, panel A). The gated cells were
stained for MHC class II DRB (panel B), WC6/DEC-205 (panel C), SIRP (panel D), and CD11b (panel E). Positive cells were determined by reference to
cells treated with normal mouse or rat serum diluted 1/1000. EGFP fluorescence was determined by comparing fluorescence levels exhibited before and after
administration of pEGFP by gene gun. Panel F shows a typical flow cytometry histogram of EGFP+ ALDC: pre-gene gun administration, unshaded histogram;
post-gene gun administration, shaded histogram.
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Fig. 2. Flow cytometry analysis of ALDC following administration of pEGFP by gene gun in four sheep observed longitudinally (A–D). ALDC were analysed
for EGFP fluorescence using the live gate shown in Fig. 1. EGFP fluorescence was determined by comparing fluorescence levels exhibited before and after
administration of pEGFP by gene gun. Panel A, sheep wt155; panel B, sheep 1345D; panel C, sheep 1766; panel D, sheep 722D.
between five sites in the drainage area of the cannulated pseu-
doafferent lymphatic duct. EGFP fluorescence in afferent
lymph cells was monitored daily by flow cytometry for as
long as the cannulated duct flowed (8, 15, 24, 35, 48, 56, 60
and 85 days, respectively). Fluorescent cells were observed
at various time points during these periods. When forward
and side scatter gates were used to differentiate the distinct
cell populations it was seen that only ALDC carried EGFP;
lymphocytes were always negative, while neutrophils occa-
sionally showed weak fluorescence. A typical flow cytometry
histogram obtained for ALDC is shown in Fig. 1. The inten-
sity of fluorescence observed in the eight sheep varied from
low to over one log above the negative control (pre-gene gun
administration).
Typical longitudinal data of EGFP+ ALDC obtained are
shown for four sheep in Fig. 2A–D. No fluorescence was dis-
cernible on ALDC in the immediate period (0–6 h) after gene
gun administration. After this lag period, small peaks of flu-
orescent DC were evident around days 1–4. Larger peaks of
fluorescence were usually observed from around day 9 post
administration onwards for several days, and in some cases up
to 60 days post administration. There were slight variations
in this pattern in other sheep with the main peaks appearing a
day or two earlier or later. The proportion of ALDC showing
fluorescence varied from a few percentage up to 90% (Fig. 2).
The peaks were sometimes restricted to single days, while in
other cases the peaks spanned over several days. In control
sheep receiving plasmid DNA encoding -gal by gene gun
or receiving no gene gun treatment, ALDC fluorescence re-
mained low over extended periods (not shown).
Analysis of the numbers of EGFP+ ALDC draining into
the afferent lymphatics is shown for six sheep in Table 1. The
numbers of EGFP+ ALDC detected over the whole collec-
tion period ranged between 3.3× 106 and 9.6× 106, with a
Table 1
Number of EGFP+ ALDC draining into the afferent lymphatics after pEGFP administration
Number of EGFP + ALDC (×106)
Sheep ID (days observed)a Total (%)b Major peak (%)c [days PI]d Average/daye
1345D (24) 3.9 (18.6) 2.9 (53.9) [8–12] 0.16
722D (56) 8.7 (13.2) 4.9 (65.2) [6–10] 0.16
WT155 (15) 3.3 (8.0) 2.4 (38.7) [11–12] 0.22
7
1
0
M
ed ALD
ed ALD41D (18) 3.7 (3.7)
766D (48) 4.7 (10.0)
62 (62) 9.6 (7.4)
edian 4.3 (11.6)
a Number of days analysed.
b Percentage of total EGFP+ALDC relative to the total number of unstain
c Percentage of total EGFP+ ALDC relative to the total number of unstain
d Days post-inoculation constituting the major peak of fluorescence.
e Number of EGFP+ ALDC/day averaged over whole observation period.3.0 (26.2) [13–15] 0.21
1.1 (30.7) [9–12] 0.10
3.7 (26.1) [22–28] 0.15
3.0 (40.1) 0.16
C.
C in the major peak.
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Table 2
Relationship between ALDC phenotypic markers and EGFP fluorescence following administration of pEGFP by gene gun
Sheep ID Dayb EGFPc fluorescence % DC positivea
CD1 SERP WC6 MHCclass 2
734D 3 + 25.7 15.2 19.4 nd
− 0.2 5.2 3.3
5 + 17.0 22.0 23.5 17.9
− 1.3 0.6 0.4 2.1
7 + nd 60.3 60.9 nd
− 4.0 2.9
Y158 3 + 25.7 15.0 19.4 nd
− 0.2 5.2 0.3
9 + 55.5 52.9 63.1 nd
− 0.0 13.6 0.0
741D 9 + 10.7 8.0 8.2 8.9
− 0.2 0.4 0.4 0.0
Median + 25.7 18.6 21.5 nd
− 0.2 4.6 0.4
P valued 0.006 0.004 0.003
a ALDC were stained for CD1, SIRP, MHC class II DRB and WC6/DEC205 using monoclonal antibodies VPM5, IL-A24, SW73.2 and IL-A53, respectively.
Untreated cells and cells treated with normal mouse or rat serum diluted 1/1000 were used as negative controls.
b Day post-gene gun administration of pEGFP.
c EGFP+ ALDC were determined by reference to ALDC prior to administration of pEGFP by gene gun; nd, not done.
d Statistical analysis of surface marker expression in EGFP+ and EGFP− ALDC subsets was performed using the Mann-Whitney rank test.
median value of 4.3× 106. These numbers represented be-
tween 3.7 and 18.6% of total ALDC collected over the whole
period, with a median value of 0.16× 106 EGFP+ ALDC per
day. The major peak of fluorescent cells gave a median value
of 3× 106 EGFP+ ALDC, and constituted a high proportion
of the total ALDC present over the peak days.
3.3. Two colour analyses of ALDC
Staining was performed in three sheep following pEGFP
administration for pan DC and subset markers. Staining per-
formed for WC6 or MHC class DR showed that almost all of
the gated ALDC were positive for these markers (usually in
excess of 95%, data not shown). In relation to EGFP+ ALDC,
it can be seen in Table 2 that the great majority of EGFP+
ALDC were WC6+. In two sheep, similar results were ob-
tained for MHC class II DR staining. EGFP+ staining resided
mainly in CD1b+ and in SIRP+ subsets irrespective of the
day of sampling postpEGFP administration. The results show
that EGFP fluorescence was associated mainly with cells dis-
playing typical DC surface markers.
3.4. Estimation of free EGFP in afferent lymph plasma
following pEGFP administration
f
b
m
n
o
to one sheep twice (Sh2558) and a second sheep three times
(Sh062). The second administration was given on day 11 and
the third on day 22. In sheep 2558, the profiles of EGFP fluo-
rescence by ALDC showed a similar pattern as in Fig. 2 after
Fig. 3. Longitudinal analysis of EGFP in afferent lymph following three
administrations of pEGFP by gene gun. Afferent lymph plasma was clarified
b
T
s
t
w
lymph plasma from sheep 062 for EGFP fluorescence; (B) flow cytometry
analysis of ALDC for EGFP fluorescence.Afferent lymph plasma was monitored by luminometry
or free EGFP on a daily basis after pEGFP administration
y gene gun. In eight sheep receiving a single pEGFP ad-
inistration, no lymph sample gave a reading that was sig-
ificantly above background levels. To determine the effect
f more than one administration, pEGFP was administeredy centrifugation and analysed for EGFP fluorescence using a fluorimeter.
he amounts of fluorescence detected were calculated with reference to a
tandard curve generated by adding known amounts of recombinant EGFP
o afferent lymph plasma from control sheep. EGFP fluorescence associated
ith ALDC was detected as described in Fig. 2. (A) luminometry analysis of
C. Watkins et al. / Vaccine 23 (2005) 4247–4256 4253
each administration, but no free EGFP was detected in plasma
(not shown). However, elevated readings for free EGFP were
obtained from afferent lymph plasma after pEGFP was given
three times in sheep 062 (Fig. 3A). The equivalent EGFP flu-
orescence detected on ALDC by flow cytometry is shown in
Fig. 3B. A large number of peaks of fluorescent ALDC were
observed from day 9 (equivalent to day 31 from first admin-
istration) onwards until day 53 (equivalent to day 75) post
administration. By reference to the standard curve generated
with rEGFP, the concentration of free EGFP ranged between
10 and 50 pg/ml of afferent lymph plasma (Fig. 3A). Using
the known total daily volumes of afferent lymph collected
and the EGFP concentrations determined by luminometry,
the total amount of EGFP detected in lymph plasma over the
whole collection period was estimated to be ∼50 ng.
3.5. Detection of pEGFP in afferent lymph following
gene gun administration
To determine if pEGFP was detectable in afferent lymph
and, if so, if it was associated with afferent lymph cells or
plasma or both following gene gun administration, the cell
and plasma fractions of afferent lymph were subjected to
PCR. Typical results obtained are shown in Figs. 4 and 5.
PCR-positive results were obtained from both plasma and the
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Fig. 5. Longitudinal PCR analysis of afferent lymph cell pellets (C) and cell
free lymph (F) for EGFP sequences following administration of pEGFP by
gene gun to five sheep (wt155, 1345D, 2558, 722D and 062). Five millil-
itres of afferent lymph were centrifuged to obtain cell pellets and cell free
lymph. The cell pellets were washed three times in PBS before extraction
of DNA. Plasmid DNA was extracted from 2 ml of cell free plasma. PCR
was performed using primers specific for pEGFP for 25 cycles. The reaction
products were run on an agarose gel and stained with ethidium bromide.
Solid bars, positive PCR results; open bars, negative PCR results; shaded
bars, not tested.
sheep, and shown to contain plasmid by PCR (Fig. 4). The
results thus showed that the plasmid persisted in skin for ex-
tended periods and drained into the afferent lymphatics in
free and cell-bound form almost on a daily basis. There was
no obvious correlation between the presence of plasmid in
afferent lymph and fluorescence by ALDC.
4. Discussion
In this study, we show for the first time that ALDC carry
antigen encoded by a plasmid DNA immunogen adminis-
tered to skin by gene gun. The ALDC were defined by their
expression of MHC class II, WC6, CD1b and SIRPmarkers.
The results make the connection between observing antigen
in skin DC [8] and antigen in DC in draining lymph nodes
[9]. In addition, our longitudinal studies show the magnitude
of antigen carriage by ALDC and the pattern of migration of
antigen-positive cells after gene gun administration. In con-
trast to the low numbers of fluorescent ALDC observed fol-
lowing intradermal injection of pEGFP [22], high proportions
of ALDC were fluorescent after gene gun administration. In
some instances, over 60% of ALDC were EGFP positive. The
results are consistent with the view that gene gun adminis-
tration is very efficient process for engaging DC [23,24].
It is thought that following DNA vaccination, DC acquire
a
t
i
pashed cell pellets for substantial proportions of the time pe-
iod observed in each sheep. Longitudinal analysis revealed
he presence of plasmid almost on a daily basis. In one sheep,
EGFP was found in afferent lymph plasma for at least 50
ays (Fig. 5). Purified CD1b+ ALDC were analysed in three
ig. 4. PCR analysis of afferent lymph cell pellets, CD1+ ALDC and lymph
lasma for EGFP sequences following administration ofpEGFP by gene gun.
A) Ethidium bromide stained gels showing EGFP PCR products generated
rom afferent lymph cell pellets from sheep 1766 (lanes 1–3), sheep 722D
lane 4), sheep 1345D (lane 5), and from clarified afferent lymph plasma from
heep 1345D (lane 6). The positive (plasmid) and negative (water) controls
re shown in lanes 7 and 8, respectively. M, molecular weight marker ladder.
B) Ethidium bromide stained gel showing EGFP PCR products generated
rom purified CD1+ ALDC from sheep 1766 (lanes 10–11), sheep 722D
lane 12), and sheep 1345D (lane 13). The positive (plasmid) and negative
water) controls are shown in lanes 9 and 14, respectively. M, molecular
eight marker ladder.ntigen either through direct transfection with plasmid or
hrough cross-priming mechanisms [11,25–27]. In our exper-
ments, the gene gun pressure was adjusted to deliver gold
articles maximally to the ovine dermal–epidermal junction.
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Thus, some Langerhans cells (LC) in the epidermis and in-
terstitial DC in the upper dermis may have been transfected
directly with plasmid-coated gold particles immediately after
gene gun administration.
Previous studies have demonstrated that keratinocytes are
the main skin cells transfected by the gene gun method
[28,29]. Thus, EGFP produced by these cells could also
have cross-primed LC, interstitial DC or ALDC with anti-
gen. However, EGFP is a non-secreted protein and may not
have been released as free protein in large amounts. Indeed,
free EGFP could not be detected by luminometry at levels
above 5 pg/ml in lymph plasma, except when priming was
followed by two boosts. It is possible that EGFP synthesised
and released in the skin may have been taken up by DC in
skin, leaving little to detect in lymph plasma. Overall, the
results suggest that either free EGFP is produced in very low
quantities or that most of it is taken up by cells in skin fol-
lowing gene gun administration, and then transported to the
draining lymph node mainly in a cell-bound form.
We observed that anti-EGFP antibody was produced fol-
lowing priming and boosting with pEGFP in non-cannulated
sheep. In previous studies, we showed that uptake of antigen
by ALDC in vitro and in vivo is greatly enhanced by the pres-
ence of antibody [30], converting a sub-stimulating dose of
antigen into a stimulating dose for T cell proliferation [31].
Indeed, the proportions of fluorescent ALDC observed here
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days, maximal at 10 days, and greatly reduced by 30 days.
Our results show that antigen traffics from the site of admin-
istration to the draining lymph node over a period of several
weeks. However, the mechanisms underlying the observed
migration patterns are unknown.
It is known that LC in skin migrate rapidly to draining
lymph nodes after skin irritation [36], infection [37], or paint-
ing with antigen [38–40]. Recent reports have shown that
plasmids containing CpG motifs also induce LC migration
in skin sheets, with 50% depletion occurring within 2 h [41].
This effect may be mediated through CpG motif recognition
by toll-like receptor 9 (TLR9) [42]. These observations sug-
gest that injection of free plasmid into skin would result in
LC uptake of plasmid via TLR9 and their rapid migration into
the afferent lymphatics. Indeed, we showed previously that
a peak of fluorescent ALDC appeared 2 h after intradermal
injection ofpEGFP [22]. Given that most of the plasmid deliv-
ered by gene gun is likely to be deposited intracellularly, the
TLR9-activation mechanism could be triggered by plasmid-
TLR9 interaction in the endosome [43]. However, plasmid
also appears in free form in lymph plasma when there are
no EGFP+ DCs in lymph. The role of plasmid-induced DC
migration is therefore uncertain. The mechanism of plasmid
release from transfected cells is unknown as is the fate of the
plasmid when it reaches the lymph node.
A recent study [12] found approximately 5× 103 antigen-
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bre similar to those observed following intradermal injec-
ion of FITC-labelled antigen into primed sheep. However,
ntibody-mediated uptake of EGFP by ALDC is unlikely in
he present study since the animals were not primed to EGFP
rior to cannulation. Also, the cannulated animals’ immune
ystem is likely to have remained naı¨ve following plasmid ad-
inistration, since all plasmids and cells draining the site of
dministration would have been removed into the collection
ottle.
The patterns of migration of fluorescent ALDC found in
his study were unexpected. These consisted of a small peak
round days 1–4, a large peak around days 9–13, and irregular
eaks at varying intervals thereafter for up to 2 months. The
esults indicate that plasmid and/or EGFP remained in the
kin over this time period. Other studies have found plasmid
ersisting at the injection site for variable periods. Udvardi
t al. [32] detected plasmid in skin up to 1 week after gene
un administration. Similarly, both plasmid and specific RNA
ere found in skin 11 days after intradermal injection by
engge et al. [33]. In other experiments, plasmid was shown
o remain at the skin injection site for 3–5 months [8] and 6–8
eeks after intramuscular injection [34]. Thus, our results
howing plasmid in afferent lymph plasma for up to 50 days
re consistent with these observations.
Protein antigen production and retention in skin, after
NA vaccination, has been examined in several studies. Yu et
l. [35] showed that antigen was detectable at 4 h, peaked be-
ween 16 and 72 h, decreased at 7 days and absent at 14 days
ollowing topical application of plasmid. Raz et al. [8], using
ntradermal injection, found that antigen was detectable by 3ositive DC in draining lymph nodes in mice following gene
un administration. This represented∼100-fold greater num-
ers than had been shown in previous studies [9]. We showed
ere that between 100,000 and 220,000 EGFP+ ALDC per
ay drained into the afferent lymphatics. On average, about
0% of total ALDC were EGFP+ over the whole course of
ollection. In individual peaks of fluorescence, between 2 and
million EGFP+ ALDC representing between 26 and 65%
f ALDC drained into the lymphatics over a period of around
days. These results indicate that large numbers of antigen-
ositive ALDC drain into the afferent lymphatics after gene
un administration of plasmid. These results suggest that pre-
ious estimates of the numbers of antigen-positive DC drain-
ng to lymph nodes [9,12] are significant underestimates.
It was also shown by Garg et al. [12] that ablation of the
njection site had no effect on the numbers of transfected
C in the lymph nodes. It was concluded that DC migration
rom skin after gene gun administration was not continuous
nd peaked after 5 days. Our results differ from these. We
ound that ALDC containing pEGFP and/or EGFP drained
nto afferent lymph for extended periods up to 2 months. The
easons for this difference are unclear, though may reflect
ifferences in the amount of plasmid administered, i.e., 15g
ersus 1.5g, or in movement of transfected cells away from
he site of administration.
The pulsitile nature of the appearance of fluorescent
LDC also remains to be explained. pEGFP does not con-
ain specific secretory sequences and it is likely that EGFP
ould remain largely intracellular. It might be speculated that
uild up of EGFP inside transfected skin cells could result in
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apoptosis. Indeed, while most studies show that EGFP gen-
erally has low toxicity, some cell lines undergo apoptosis or
necrosis following EGFP expression [44,45]. It is conceivable
that some cell types in vivo may thus undergo apoptosis due
to EGFP expression. It might be envisaged that successive
rounds of apoptosis in transfected skin cells in vivo may re-
sult in the generation of apoptotic bodies containing plasmid
and/or EGFP. Since DC can take up apoptotic bodies effi-
ciently [46], LC and other skin DC could acquire such apop-
totic bodies and appear as peaks of fluorescent ALDC. How-
ever, Garg et al. [12] used a mutated caspase-2 gene to induce
slow apoptosis of gene gun transfected cells and concluded
that antigen positivity of DC in draining lymph nodes was not
due to transfer from dead cells to live cells. Recently, DCs
have been shown to capture antigen from live cells by a ‘nib-
bling’ process [47]. Continual nibbling of EGFP-containing
cells could provide a mechanism for EGFP acquisition by
skin DC without involving apoptosis or necrosis, but does
not in itself explain the pulsitile appearance of antigen-laden
DC in afferent lymph. Further work is required to elucidate
the mechanisms underlying the observed migration patterns
of fluorescent ALDC following gene gun administration of
EGFP plasmid.
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